Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.39 |
| ▸ | FEN1 | P39748 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17487599 | 0.85 | PDE2A (0.35) | PDE2AEPHX2FAAHCTSKNAAA | |
| SCHEMBL18134240 | 0.85 | PTGS2 (0.43) | PDE2AEPHX2ALOX5APFEN1CTSK | |
| SCHEMBL20380750 | 0.85 | ALOX5AP (0.41) | PDE2AALOX5APFEN1FAAHCTSK | |
| SCHEMBL20380631 | 0.83 | FFAR4 (0.37) | PDE2AEPHX2ALOX5APFEN1FAAH | |
| SCHEMBL20380665 | 0.83 | FFAR4 (0.35) | PDE2AEPHX2ALOX5APFEN1FAAH | |
| SCHEMBL16852368 | 0.83 | PTGS2 (0.49) | PTGS2 | |
| SCHEMBL20010568 | 0.82 | FGFR2 (0.41) | PDE2AEPHX2ALOX5APFEN1FAAH | |
| SCHEMBL17365885 | 0.82 | EPHX2 (0.43) | PDE2AEPHX2ALOX5APFEN1FAAH | |
| SCHEMBL18887714 | 0.81 | ALOX5AP (0.42) | PDE2AEPHX2ALOX5APFEN1FAAH | |
| SCHEMBL20380564 | 0.81 | ALOX5AP (0.37) | PDE2AEPHX2ALOX5APFEN1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4279565-A2 | THIOPHENE COMPOUND, LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | Merck Patent GmbH (DE) | 2023-11-22 | — | — | EP | disclosed |
| EP-3679111-B1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | MERCK PATENT GMBH (DE) | 2023-11-01 | — | — | EP | disclosed |
| US-11795398-B2 | Liquid-crystalline medium and liquid-crystal display comprising the same and compounds | MERCK PATENT GMBH (DE) | 2023-10-24 | — | — | US | disclosed |
| US-11795398-B2 | Liquid-crystalline medium and liquid-crystal display comprising the same and compounds | MERCK PATENT GMBH (DE) | 2023-10-24 | — | — | US | disclosed |
| EP-3877484-B1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | MERCK PATENT GMBH (DE) | 2023-09-13 | — | — | EP | disclosed |
| EP-3763802-B1 | THIOPHENE COMPOUND, LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | MERCK PATENT GMBH (DE) | 2023-09-06 | — | — | EP | disclosed |
| US-20230045269-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | MERCK PATENT GMBH (DE) | 2023-02-09 | — | — | US | disclosed |
| US-11447701-B2 | Liquid-crystalline medium and liquid-crystal display comprising the same and compounds | MERCK PATENT GMBH (DE) | 2022-09-20 | — | — | US | disclosed |
| WO-2022136223-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME AND COMPOUNDS | MERCK PATENT GMBH (DE) | 2022-06-30 | — | — | WO | disclosed |
| EP-4015599-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | Merck Patent GmbH (DE) | 2022-06-22 | — | — | EP | disclosed |
| US-20180086980-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | MERCK PATENT GMBH (DE) | 2018-03-29 | — | — | US | disclosed |
| US-20180086980-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | MERCK PATENT GMBH (DE) | 2018-03-29 | — | — | US | disclosed |
| EP-3299438-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | Merck Patent GmbH (DE) | 2018-03-28 | — | — | EP | disclosed |
| US-20170335190-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | MERCK PATENT GMBH (DE) | 2017-11-23 | — | — | US | disclosed |
| US-20170335190-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | MERCK PATENT GMBH (DE) | 2017-11-23 | — | — | US | disclosed |
| US-20170292072-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | MERCK PATENT GMBH (DE) | 2017-10-12 | — | — | US | disclosed |
| US-20170292072-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | MERCK PATENT GMBH (DE) | 2017-10-12 | — | — | US | disclosed |
| EP-3228681-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | Merck Patent GmbH (DE) | 2017-10-11 | — | — | EP | disclosed |
| US-20160298033-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | MERCK PATENT GMBH (DE) | 2016-10-13 | — | — | US | disclosed |
| US-20160298033-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | MERCK PATENT GMBH (DE) | 2016-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447701-B2 | Liquid-crystalline medium and liquid-crystal display comprising the same and compounds | NEFM, FES, SBDS | PDE2A 1557/4885EPHX2 2946/4885ALOX5AP 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.